4results about How to "Block binding" patented technology

The invention discloses a cigarette smoke sweetness improving method based on bitterness masking and sweetness synergistic regulation, which comprises the following steps: preparing a dual regulating agent: compounding a bitterness masking agent and a sweetness synergist according to a preset mass ratio, and dissolving or dispersing in a solvent to form the dual regulating agent; the dual regulating agent is applied to a cigarette carrier, and the cigarette material is obtained; and balancing the treated cigarette material and rolling the cigarette material into cigarettes. According to the cigarette smoke sweetness improving method based on bitter taste masking and sweetness synergistic regulation, starting from the system level of sensory interaction, through a dual sensory regulation mechanism of bitter taste masking and sweetness synergistic, the cigarette smoke sweetness perception is synergistically improved, the sweetness signal is improved, meanwhile, background bitter taste interference is effectively inhibited, and the cigarette smoke sweetness improving effect is achieved. Therefore, efficient, pure and natural improvement of the sweetness is realized; the defects of low efficiency and unnatural sweetness of the traditional single sweetening agent are overcome, and a novel way which is more systematic, more efficient and capable of comprehensively improving the taste of the smoke is provided.

This invention discloses a polypeptide targeting IL-17RA and a lysosomal targeting chimera and their application in the treatment of psoriasis, relating to the biomedical field. The amino acid sequence of the polypeptide targeting IL-17RA has at least 80% identity with the sequence shown in SEQ ID NO:1 or 2. It has a high affinity for IL-17RA protein and can effectively block the binding of IL-17RA protein and IL-17A protein. The lysosomal targeting chimera constructed using this polypeptide molecule has excellent therapeutic effects and good biocompatibility for psoriasis, and has good application prospects in the treatment or adjuvant treatment of psoriasis.

This invention relates to monoclonal antibodies against CTLA4 or their antigen-binding fragments, pharmaceutical compositions, and uses. The invention belongs to the fields of tumor therapy and molecular immunology, providing monoclonal antibodies against CTLA4 or their antigen-binding fragments, pharmaceutical compositions thereof, and their uses. The monoclonal antibodies of this invention can block the binding of CTLA4 to B7, relieve the immunosuppression caused by CTLA4, and activate T lymphocytes.

This invention discloses a competitive monoclonal antibody against bovine ephemeral fever virus (BOF) and its application in constructing a competitive ELISA kit, belonging to the field of monoclonal antibody technology. The technical problem this invention aims to solve is how to accurately detect BEF. This invention provides a competitive monoclonal antibody against BEF, wherein the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.2; and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.7. This enables rapid and accurate diagnosis of BEF, facilitating timely implementation of prevention and control measures and reducing the risk of epidemic transmission.